Pfizer and Merck to Collaborate on Study Evaluating Novel Anti-Cancer Combination Regimen
Dateline City:
WHITEHOUSE STATION, N.J.
Agreement to Combine Merck’s Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizer’s crizotinib (XALKORI®) in Clinical Trial
WHITEHOUSE STATION, N.J. – Pfizer Inc. (NYSE:PFE) and Merck & Co. Inc. (NYSE: MRK), known as MSD outside the United States and Canada, through a subsidiary, announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib (XALKORI®) with Merck’s investigational anti-PD-1 antibody pembrolizumab, in a Phase 1b clinical study evaluating the safety and tolerability of the combination in patients with ALK-positive advanced or metastatic non-small cell lung cancer (NSCLC).
Language:
English
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Merck | Non-Small Cell Lung Cancer | Pfizer | Pharmaceuticals | Study